Foghorn Therapeutics Inc. (FHTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 6M 12M 18M Q3 '21: 41K Q4 '21: 713K Q1 '22: 3.9M Q2 '22: 4.5M Q3 '22: 6.6M Q4 '22: 4.2M Q1 '23: 5.3M Q2 '23: 5.6M Q3 '23: 17.5M Q4 '23: 5.8M Q1 '24: 5M Q2 '24: 6.9M Q3 '24: 7.8M Q4 '24: 2.9M Q1 '25: 6M Q2 '25: 7.6M Q3 '25: 8.2M Q4 '25: 9.2M Q1 '26: 3.3M Q2 '26: 16.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -26.3M Q4 '21: -28.1M Q1 '22: -27.8M Q2 '22: -29.2M Q3 '22: -28.3M Q4 '22: -31.9M Q1 '23: -33.3M Q2 '23: -32M Q3 '23: -17.1M Q4 '23: -25.5M Q1 '24: -28.2M Q2 '24: -26.6M Q3 '24: -23.9M Q4 '24: -24M Q1 '25: -22.9M Q2 '25: -21.1M Q3 '25: -18.5M Q4 '25: -23.9M Q1 '26: -21.6M Q2 '26: -8.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -26.1M Q4 '21: -29.1M Q1 '22: -26.9M Q2 '22: -27.3M Q3 '22: -25.8M Q4 '22: -28.9M Q1 '23: -30.5M Q2 '23: -29.5M Q3 '23: -14.3M Q4 '23: -24.1M Q1 '24: -25M Q2 '24: -23M Q3 '24: -19.1M Q4 '24: -19.5M Q1 '25: -18.8M Q2 '25: -17.9M Q3 '25: -15.8M Q4 '25: -21.7M Q1 '26: -19.9M Q2 '26: -7.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-100M 0 100M 200M 300M Q3 '21: -20.5M Q4 '21: 11.9M Q1 '22: 271.5M Q2 '22: -29M Q3 '22: -20M Q4 '22: -28.9M Q1 '23: -31.2M Q2 '23: -32.2M Q3 '23: -27.2M Q4 '23: -27.5M Q1 '24: -29.3M Q2 '24: -25.5M Q3 '24: -21M Q4 '24: -24.5M Q1 '25: -24M Q2 '25: -21M Q3 '25: -18.9M Q4 '25: -22.3M Q1 '26: -25.3M Q2 '26: -17.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-100M 0 100M 200M 300M Q3 '21: -20.7M Q4 '21: 11.8M Q1 '22: 271.3M Q2 '22: -29.4M Q3 '22: -20.3M Q4 '22: -29.2M Q1 '23: -31.8M Q2 '23: -32.6M Q3 '23: -27.3M Q4 '23: -27.6M Q1 '24: -29.4M Q2 '24: -25.6M Q3 '24: -21.3M Q4 '24: -25M Q1 '25: -24M Q2 '25: -21M Q3 '25: -18.9M Q4 '25: -22.3M Q1 '26: -25.3M Q2 '26: -17.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '20: 5.4M Q3 '20: 5.9M Q1 '21: 36.8M Q2 '21: 36.8M Q3 '21: 37M Q1 '22: 41.4M Q2 '22: 41.5M Q3 '22: 41.7M Q1 '23: 41.8M Q2 '23: 41.8M Q3 '23: 42M Q1 '24: 42.4M Q2 '24: 51.6M Q3 '24: 62.6M Q1 '25: 62.8M Q2 '25: 63M Q3 '25: 63M Q1 '26: 69.5M Q2 '26: 70.6M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -2.00 -1.00 0.00 1.00 2.00 3.00 Q3 '21: 0.54 Q4 '21: -2.73 Q1 '22: -2.76 Q2 '22: -2.79 Q3 '22: -2.70 Q4 '22: -2.62 Q1 '23: -2.70 Q2 '23: -2.74 Q3 '23: -2.46 Q4 '23: -2.34 Q1 '24: -2.20 Q2 '24: -1.95 Q3 '24: -1.92 Q4 '24: -1.65 Q1 '25: -1.36 Q2 '25: -1.19 Q3 '25: -1.13 Q4 '25: -1.17 Q1 '26: -1.16 Q2 '26: -0.98 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.